Want to join the conversation?
$DGX posted higher earnings in 2Q16, favorably impacted by the gain on sale of its Focus Diagnostics products business of $34MM after tax or $0.24 per diluted share. Net income was $195MM or $1.37 per diluted share, compared to $118MM or $0.81 per diluted share last year. Revenue fell 1% from 2Q15 to $1.91Bil. Adjusted diluted EPS was $1.34.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.